To fulfill the need for global biometrics solutions, CROS NT SRL today announced the acquisition of Stat?Tech Services, LLC ? a Contract Research Organization (CRO) with extensive experience in the medical devices sector.
To fulfill the need for global biometrics solutions, CROS NT SRL today announced the acquisition of Stat‐Tech Services, LLC ‐ a Contract Research Organization (CRO) with extensive experience in the medical devices sector. The financial details of the transaction remain confidential.
CROS NT, an international CRO, specializes in biometrics services, and sees the acquisition as an important part of their overall strategy. The deal adds the US to Italy, Germany, and the UK; increasing CROS NT’s geographical reach while adding critical mass to its operation. Stat‐Tech has an excellent reputation for quality and service making it an obvious target for CROS NT, which is seeking to expand while maintaining service excellence.
Paolo Morelli, CEO and President of CROS NT, said, “I am delighted to welcome Stat‐Tech services into the family. The experience and quality of the Stat‐Tech team will add strong value to CROS NT, adding the important area of Medical Devices to our portfolio and allowing us to improve our services to our existing US customers by being closer to them. I was impressed by the reputation of their management and their strong leadership, which we can combine with the existing groups in Europe to field a great team globally.”
“I believe that having highly qualified specialists delivers the best results when conducting clinical trials. CROS NT remains focused on biometrics and by providing expert data services allows its customers to work with clinical CROs appropriate to their therapeutic or geographic needs. We take care of the data collection and the reporting and provide centralized data solutions to maximize the value of those data to the customer,” Paolo added.
George DeMuth, one of the founders of Stat‐Tech Services, LLC and incoming Chief Operating Officer, US Operations, said, “We are very excited about joining CROS NT. This move allows us to provide a broader range of services and additional resources to our existing clients; and provides additional opportunities for growth. CROS NT has a high level of expertise to go with a focus on quality and service; so we knew immediately Stat‐Tech was joining a great team.”
Stat‐Tech Services, LLC is based in Chapel Hill, NC and has been providing biometrics services since 1996. The company has supported numerous approvals in medical devices (501(k)s and PMAs), biologics, and pharmaceutical indications. In addition to data management, study design, and data analysis, Stat‐Tech Services has been involved in numerous FDA interactions including FDA panel meetings.
Stat‐Tech will operate as a business line within CROS NT, trading as “Stat‐Tech Services, part of CROS NT Group.” The transaction is due to complete later this month.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Truqap Combination Shines in Phase III Trial for Prostate Cancer
November 26th 2024Data from the CAPItello-281 trial show Truqap alongside abiraterone and androgen deprivation therapy achieved a statistically significant and clinically meaningful improvement in radiographic progression-free survival.
Empowering Sites and Patients: The Impact of Personalized Support in Clinical Trials
November 26th 2024To meet the growing demands of clinical research, sponsors must prioritize comprehensive support models, such as clinical site ambassadors and patient journey coordinators, who can address operational challenges and improve site relationships, patient satisfaction, and overall trial efficiency.